RSL3

SKU: orb1303961

Description

RSL3 is a potent and selective ferroptosis inducer that functions by inhibiting GPX4 and system xc- (IC50=100 nM), thereby depleting glutathione. It effectively triggers cell death in oncogenic RAS-harboring tumor cells and is widely used in vitro and in vivo to study ferroptosis mechanisms in cancer research.

Research Area

Cell Biology, Neuroscience

Key Properties

• CAS Number: 1219810-16-8
• MW: 440.9
• Purity: >98%
• Formula: C₂₃H₂₁ClN₂O₅
• SMILES: COC(=O)[C@H]1Cc2c([nH]c3ccccc23)[C@@H](N1C(=O)CCl)c1ccc(cc1)C(=O)OC
• Target: Glutathione
• Solubility: Soluble in DMSO (up to 45 mg/ml)

Bioactivity

• Target IC50:
  4T1 cells:3.69 μM|GSH:100 nM|MCF-7 cells (24 h):13.57 μM|HT1080 cells:1.2 μM
• In Vivo:
  METHODS: To test the antitumor activity in vivo, RSL3 (100 mg/kg in 20 μL DMSO plus 80 μL corn oil) was intraperitoneally injected into NSG mice bearing human prostate cancer tumors DU145 or PC3 twice a week for sixteen days. RESULTS: RSL3 treatment significantly inhibited the growth of human prostate cancer tumors, indicating antitumor activity in vivo. METHODS: To detect anti-tumor activity in vivo, RSL3 (1 mg/kg) and cetuximab (13 mg/kg) were intraperitoneally injected once a week for sixteen days into BALB/c nude mice harboring KRAS-mutant human colorectal cancer tumor DLD-1. RESULTS: RSL3 treatment significantly inhibited the growth of KRAS-mutant tumors. Cetuximab enhanced RSL3-induced ferroptosisby activating p38 MAPK and inhibiting the Nrf2/HO-1 axis, which further inhibited tumor growth.
• In Vitro:
  METHODS: Human hepatocellular carcinoma cells HepG2, HA22T/VGH were treated with RSL3 (0.1-10 μM) for 72 h, and cell growth inhibition was detected by MTT. RESULTS: RSL3 dose-dependently inhibited the growth of HepG2 and HA22T/VGH cells, with an IC50 of about 0.07 μM for HepG2 cells and 0.3 μM for HA22T/VGH cells. METHODS: Human glioblastoma cells U87 and U251 were treated with RSL3 (0.25 μM and 0.5 μM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: RSL3 treatment induced a decrease in the expression of ferroptosis-related proteins GPX4, ATF4 and xCT, and an up-regulation in the expression of HO-1 in U87 and U251 cells. METHODS: Human colorectal cancer cells HCT116 and LoVo were treated with RSL3 (3 μM) for 24 h. Labile iron pool (LIP) and ROS intracellular levels were analyzed by Flow Cytometry. RESULTS: RSL3 promoted the increase of LIP and accumulation of ROS associated with ferroptosis.
• Cell Research:
  TERT/LT/ST/RASV12 cells are seeded in 10 cm dishes and treated with 1 µM staurosporine, 10 µg/ml erastin, 20 µg/ml RSL5, and 1 µg/ml RSL3 for 16 hr. Both dying cells and live cells in each 10 cm dish are harvested and collected in the same 15 ml tubes by centrifuging cell suspension at 1000 rpm for 5 min. (Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

1S,3R-RSL3

Compound Identifiers

PubChem CID

1750826